{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:02:58Z","timestamp":1790870578491,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002345","name":"Eberhard Karls Universit\u00e4t T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002345","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Beyond microsurgical resection and radiation therapy, there are currently no established treatment alternatives for meningioma patients. In selected cases, peptide radio receptor therapy (PRRT) can be implemented. For this purpose, a radionuclide is bound to a substance targeting specific receptors in meningiomas. One of them is somatostatin receptor 2, which can be found in most meningiomas. However, other somatostatin receptors (SSTR) exist, but their expressions have only been described in small case series. In this study, we analyzed the expression of SSTR1, 2A, 3, 4, and 5 in a large cohort of meningiomas in order to enable further refinement of this innovative treatment option. Overall, 726 tumor samples were processed into tissue microarrays and stained for SSTR1, 2A, 3, 4, and 5 immunohistochemically. Microscopic evaluation was done with an established semiquantitative score regarding percentual quantification and staining intensity, and results were correlated with clinical data. There was a significant lower rate of SSTR1 expression in meningiomas of male patients. Older age was associated with higher expression of SSTR1, 2A, and 5 and lower scores for SSTR3 and 4. Tumors treated with radiotherapy before resection showed lower rates of SSTR1 and 5 expression, while recurrent meningiomas had lower SSTR1 scores. Tumor tissue from patients suffering from neurofibromatosis type 2 had lower expression scores for SSTR1, 2, and 5. For SSTR3 and 4, NF2 patients showed higher scores than sporadic tumors. Spinal meningiomas had higher scores for SSTR1, 4, and 5 compared tumor location of the skull base and convexity\/falx. Overall, higher WHO grade was associated with lower SSTR scores. While all SSTRs were expressed, there are marked differences of SSTR expression between meningioma subgroups. This has the potential to drive the development of more selective PRRT substances with higher treatment efficacy.<\/jats:p>","DOI":"10.1007\/s10143-021-01552-y","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T02:02:22Z","timestamp":1619402542000},"page":"467-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Differences in the expression of SSTR1\u20135 in meningiomas and its therapeutic potential"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1083-1276","authenticated-orcid":false,"given":"Felix","family":"Behling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Fodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Skardelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Renovanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Castaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazaleh","family":"Tabatabai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Honegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Tatagiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-6209","authenticated-orcid":false,"given":"Jens","family":"Schittenhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,26]]},"reference":[{"key":"1552_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/0883073816666736","volume":"32","author":"S Ardern-Holmes","year":"2017","unstructured":"Ardern-Holmes S, Fisher G, North K (2017) Neurofibromatosis Type 2. J Child Neurol 32:9\u201322. https:\/\/doi.org\/10.1177\/0883073816666736","journal-title":"J Child Neurol"},{"key":"1552_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/b:neon.0000013498.19981.55","volume":"66","author":"S Arena","year":"2004","unstructured":"Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, Dadati P, Dorcaratto A, Lapertosa G, Ravetti JL, Spaziante R, Schettini G, Florio T (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66:155\u2013166. https:\/\/doi.org\/10.1023\/b:neon.0000013498.19981.55","journal-title":"J Neurooncol"},{"key":"1552_CR3","first-page":"485","volume":"20","author":"V Barresi","year":"2008","unstructured":"Barresi V, Alafaci C, Salpietro F, Tuccari G (2008) Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep 20:485\u2013492","journal-title":"Oncol Rep"},{"key":"1552_CR4","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","volume":"36","author":"M Bartolomei","year":"2009","unstructured":"Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Arico D, Sansovini M, Paganelli G (2009) Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36:1407\u20131416. https:\/\/doi.org\/10.1007\/s00259-009-1115-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1552_CR5","doi-asserted-by":"publisher","first-page":"i18","DOI":"10.1093\/neuonc\/noy136","volume":"21","author":"PK Brastianos","year":"2019","unstructured":"Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR, International Consortium on M (2019) Advances in multidisciplinary therapy for meningiomas. Neuro Oncol 21:i18\u2013i31. https:\/\/doi.org\/10.1093\/neuonc\/noy136","journal-title":"Neuro Oncol"},{"key":"1552_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/s12032-014-0866-y","volume":"31","author":"M Buglione","year":"2014","unstructured":"Buglione M, De Bari B, Trevisan F, Ghirardelli P, Pedretti S, Triggiani L, Magrini SM (2014) Role of external beam radiotherapy in the treatment of relapsing meningioma. Med Oncol 31:866. https:\/\/doi.org\/10.1007\/s12032-014-0866-y","journal-title":"Med Oncol"},{"key":"1552_CR7","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","volume":"69","author":"MC Chamberlain","year":"2007","unstructured":"Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69:969\u2013973. https:\/\/doi.org\/10.1212\/01.wnl.0000271382.62776.b7","journal-title":"Neurology"},{"key":"1552_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yasuno K, Gunel M (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077\u20131080. https:\/\/doi.org\/10.1126\/science.1233009","journal-title":"Science"},{"key":"1552_CR9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/cbr.2014.1741","volume":"30","author":"A Dash","year":"2015","unstructured":"Dash A, Chakraborty S, Pillai MR, Knapp FF Jr (2015) Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm 30:47\u201371. https:\/\/doi.org\/10.1089\/cbr.2014.1741","journal-title":"Cancer Biother Radiopharm"},{"key":"1552_CR10","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/RLU.0000000000002328","volume":"44","author":"MS Dressen","year":"2019","unstructured":"Dressen MS, Muthukrishnan A, Tragon TR, Lieberman FS, Mountz JM (2019) Complementary molecular and metabolic characterization of meningiomas with DOTATATE and FDG-PET: advancing treatment planning and prognostication. Clin Nucl Med 44:e26\u2013e27. https:\/\/doi.org\/10.1097\/RLU.0000000000002328","journal-title":"Clin Nucl Med"},{"key":"1552_CR11","doi-asserted-by":"crossref","unstructured":"Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC (1998) Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76:620\u2013627","DOI":"10.1002\/(SICI)1097-0215(19980529)76:5<620::AID-IJC2>3.0.CO;2-S"},{"key":"1552_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/bip.10256","volume":"66","author":"S Froidevaux","year":"2002","unstructured":"Froidevaux S, Eberle AN (2002) Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 66:161\u2013183. https:\/\/doi.org\/10.1002\/bip.10256","journal-title":"Biopolymers"},{"key":"1552_CR13","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","volume":"56","author":"K Gerster-Gillieron","year":"2015","unstructured":"Gerster-Gillieron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D (2015) 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med 56:1748\u20131751. https:\/\/doi.org\/10.2967\/jnumed.115.155853","journal-title":"J Nucl Med"},{"key":"1552_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11060-018-2929-y","volume":"140","author":"V Gilard","year":"2018","unstructured":"Gilard V, Goia A, Ferracci FX, Marguet F, Magne N, Langlois O, Perez A, Derrey S (2018) Spinal meningioma and factors predictive of post-operative deterioration. J Neurooncol 140:49\u201354. https:\/\/doi.org\/10.1007\/s11060-018-2929-y","journal-title":"J Neurooncol"},{"key":"1552_CR15","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","volume":"17","author":"R Goldbrunner","year":"2016","unstructured":"Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Moyal EC, Brandsma D, Henriksson R, Soffietti R, Weller M (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383-391. https:\/\/doi.org\/10.1016\/S1470-2045(16)30321-7","journal-title":"Lancet Oncol"},{"key":"1552_CR16","doi-asserted-by":"publisher","first-page":"55361","DOI":"10.18632\/oncotarget.19517","volume":"8","author":"T Graillon","year":"2017","unstructured":"Graillon T, Romano D, Defilles C, Lisbonis C, Saveanu A, Figarella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Barlier A (2017) Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro. Oncotarget 8:55361\u201355373. https:\/\/doi.org\/10.18632\/oncotarget.19517","journal-title":"Oncotarget"},{"key":"1552_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","volume":"26","author":"T Graillon","year":"2020","unstructured":"Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyriere H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honore S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL (2020) Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial. Clin Cancer Res 26:552\u2013557. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2109","journal-title":"Clin Cancer Res"},{"key":"1552_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00259-012-2124-x","volume":"39","author":"H Hanscheid","year":"2012","unstructured":"Hanscheid H, Sweeney RA, Flentje M, Buck AK, Lohr M, Samnick S, Kreissl M, Verburg FA (2012) PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging 39:1284\u20131288. https:\/\/doi.org\/10.1007\/s00259-012-2124-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1552_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ctro.2020.03.002","volume":"22","author":"PE Hartrampf","year":"2020","unstructured":"Hartrampf PE, Hanscheid H, Kertels O, Schirbel A, Kreissl MC, Flentje M, Sweeney RA, Buck AK, Polat B, Lapa C (2020) Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol 22:29\u201332. https:\/\/doi.org\/10.1016\/j.ctro.2020.03.002","journal-title":"Clin Transl Radiat Oncol"},{"key":"1552_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3171\/jns.1997.86.1.0113","volume":"86","author":"DW Hsu","year":"1997","unstructured":"Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113\u2013120. https:\/\/doi.org\/10.3171\/jns.1997.86.1.0113","journal-title":"J Neurosurg"},{"key":"1552_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.nec.2015.11.002","volume":"27","author":"M Karsy","year":"2016","unstructured":"Karsy M, Guan J, Cohen A, Colman H, Jensen RL (2016) Medical management of meningiomas: current status, failed treatments, and promising horizons. Neurosurg Clin N Am 27:249\u2013260. https:\/\/doi.org\/10.1016\/j.nec.2015.11.002","journal-title":"Neurosurg Clin N Am"},{"key":"1552_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1046\/j.1365-2559.2003.01712.x","volume":"43","author":"AE Konstantinidou","year":"2003","unstructured":"Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakis X, Hranioti S, Eftychiadis C, Patsouris E (2003) Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43:280\u2013290. https:\/\/doi.org\/10.1046\/j.1365-2559.2003.01712.x","journal-title":"Histopathology"},{"key":"1552_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1748-717X-7-99","volume":"7","author":"MC Kreissl","year":"2012","unstructured":"Kreissl MC, Hanscheid H, Lohr M, Verburg FA, Schiller M, Lassmann M, Reiners C, Samnick SS, Buck AK, Flentje M, Sweeney RA (2012) Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol 7:99. https:\/\/doi.org\/10.1186\/1748-717X-7-99","journal-title":"Radiat Oncol"},{"key":"1552_CR24","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124\u20132130. https:\/\/doi.org\/10.1200\/JCO.2007.15.2553","journal-title":"J Clin Oncol"},{"key":"1552_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1210\/edrv-12-4-450","volume":"12","author":"SW Lamberts","year":"1991","unstructured":"Lamberts SW, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450\u2013482. https:\/\/doi.org\/10.1210\/edrv-12-4-450","journal-title":"Endocr Rev"},{"key":"1552_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820. https:\/\/doi.org\/10.1007\/s00401-016-1545-1","journal-title":"Acta Neuropathol"},{"key":"1552_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/cbr.2013.1599","volume":"29","author":"F Minutoli","year":"2014","unstructured":"Minutoli F, Amato E, Sindoni A, Cardile D, Conti A, Herberg A, Baldari S (2014) Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature. Cancer Biother Radiopharm 29:193\u2013199. https:\/\/doi.org\/10.1089\/cbr.2013.1599","journal-title":"Cancer Biother Radiopharm"},{"key":"1552_CR28","doi-asserted-by":"publisher","first-page":"R551","DOI":"10.1530\/ERC-16-0151","volume":"23","author":"K Oberg","year":"2016","unstructured":"Oberg K, Lamberts SW (2016) Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer 23:R551\u2013R566. https:\/\/doi.org\/10.1530\/ERC-16-0151","journal-title":"Endocr Relat Cancer"},{"key":"1552_CR29","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016. Neuro Oncol 21:v1\u2013v100. https:\/\/doi.org\/10.1093\/neuonc\/noz150","journal-title":"Neuro Oncol"},{"issue":"Suppl 1","key":"1552_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000080742","volume":"80","author":"JC Reubi","year":"2004","unstructured":"Reubi JC (2004) Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl 1):51\u201356. https:\/\/doi.org\/10.1159\/000080742","journal-title":"Neuroendocrinology"},{"key":"1552_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/s0165-6147(00)88992-0","volume":"16","author":"JC Reubi","year":"1995","unstructured":"Reubi JC, Laissue JA (1995) Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 16:110\u2013115. https:\/\/doi.org\/10.1016\/s0165-6147(00)88992-0","journal-title":"Trends Pharmacol Sci"},{"key":"1552_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0002-9440(10)65564-2","volume":"153","author":"JC Reubi","year":"1998","unstructured":"Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A (1998) Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 153:233\u2013245. https:\/\/doi.org\/10.1016\/S0002-9440(10)65564-2","journal-title":"Am J Pathol"},{"key":"1552_CR33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00401-013-1093-x","volume":"125","author":"DE Reuss","year":"2013","unstructured":"Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, Kickingereder P, Mucha J, Koelsche C, Jager N, Santarius T, Tarpey PS, Stephens PJ, Andrew Futreal P, Wellenreuther R, Kraus J, Lenartz D, Herold-Mende C, Hartmann C, Mawrin C, Giese N, Eils R, Collins VP, Konig R, Wiestler OD, Pfister SM, von Deimling A (2013) Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125:351\u2013358. https:\/\/doi.org\/10.1007\/s00401-013-1093-x","journal-title":"Acta Neuropathol"},{"key":"1552_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.59.2.3","volume":"59","author":"D Ribatti","year":"2007","unstructured":"Ribatti D, Conconi MT, Nussdorfer GG (2007) Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev 59:185\u2013205. https:\/\/doi.org\/10.1124\/pr.59.2.3","journal-title":"Pharmacol Rev"},{"key":"1552_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3171\/2014.7.JNS131644","volume":"122","author":"L Rogers","year":"2015","unstructured":"Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122:4\u201323. https:\/\/doi.org\/10.3171\/2014.7.JNS131644","journal-title":"J Neurosurg"},{"key":"1552_CR36","first-page":"1865","volume":"6","author":"S Schulz","year":"2000","unstructured":"Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, Hollt V (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6:1865\u20131874","journal-title":"Clin Cancer Res"},{"key":"1552_CR37","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/neuonc\/now060","volume":"18","author":"K Seystahl","year":"2016","unstructured":"Seystahl K, Stoecklein V, Schuller U, Rushing E, Nicolas G, Schafer N, Ilhan H, Pangalu A, Weller M, Tonn JC, Sommerauer M, Albert NL (2016) Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake. Neuro Oncol 18:1538\u20131547. https:\/\/doi.org\/10.1093\/neuonc\/now060","journal-title":"Neuro Oncol"},{"key":"1552_CR38","first-page":"13185","volume":"8","author":"CB Silva","year":"2015","unstructured":"Silva CB, Ongaratti BR, Trott G, Haag T, Ferreira NP, Leaes CG, Pereira-Lima JF, Oliveira Mda C (2015) Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol 8:13185\u201313192","journal-title":"Int J Clin Exp Pathol"},{"key":"1552_CR39","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","volume":"34","author":"M Theodoropoulou","year":"2013","unstructured":"Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228\u2013252. https:\/\/doi.org\/10.1016\/j.yfrne.2013.07.005","journal-title":"Front Neuroendocrinol"},{"key":"1552_CR40","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-14-0488","volume":"172","author":"WA van der Zwan","year":"2015","unstructured":"van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ (2015) GEPNETs update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol 172:R1-8. https:\/\/doi.org\/10.1530\/EJE-14-0488","journal-title":"Eur J Endocrinol"},{"key":"1552_CR41","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2174\/1381612023393756","volume":"8","author":"I Virgolini","year":"2002","unstructured":"Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R (2002) Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 8:1781\u20131807. https:\/\/doi.org\/10.2174\/1381612023393756","journal-title":"Curr Pharm Des"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-021-01552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-021-01552-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-021-01552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T06:03:21Z","timestamp":1644386601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-021-01552-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1007\/s10143-021-01552-y","relation":{},"ISSN":["0344-5607","1437-2320"],"issn-type":[{"value":"0344-5607","type":"print"},{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,26]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Clinical Ethics Committee of the University of T\u00fcbingen (Project number: 618\/2014BO2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Tumor tissue and clinical data were only used if patient consent was available as defined by the Clinical Ethics Committee of the University of T\u00fcbingen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}